The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers.

Published on Sep 1, 2019in Cancer Treatment Reviews8.33
· DOI :10.1016/j.ctrv.2019.08.003
Francesco Gelsomino13
Estimated H-index: 13
Giuseppe Lamberti3
Estimated H-index: 3
+ 4 AuthorsAndrea Ardizzoni48
Estimated H-index: 48
View in Source
Abstract Small cell lung cancer (SCLC) was defined as a “recalcitrant cancer” because of its dismal prognosis and lack of outcome improvements in the last 30 years. Immunotherapy with checkpoint inhibitors revolutionized treatment in many cancer types and results from the IMpower133 study, a double-blind placebo-controlled phase III trial, showed overall survival benefit for atezolizumab when added to standard platinum-etoposide chemotherapy in first-line SCLC setting for the first time since years. Trials with other checkpoint inhibitors, e.g. pembrolizumab, durvalumab, nivolumab and ipilimumab, are ongoing in various settings, but, to date, there are no defined factors to identify patients who are more likely to benefit from such treatments. This review summarizes results of immunotherapy trials in SCLC for first-line, maintenance and further-line therapies for single-agents and combinations with checkpoint inhibitors. Predictive factors from these trials are reviewed in order to identify their clinical value, with particular emphasis on PD-L1 expression on both tumor cells and in stroma, especially in pembrolizumab-treated patients, and tumor mutational burden, for patients treated with the ipilimumab and nivolumab combination.
  • References (71)
  • Citations (0)
#1B. Ricciuti (Harvard University)H-Index: 3
#2Sasha Kravets (Harvard University)H-Index: 3
Last.Mark M. Awad (Harvard University)H-Index: 38
view all 10 authors...
3 CitationsSource
#1Anish ThomasH-Index: 24
#2Rasa VilimasH-Index: 1
Last.Jung-Min LeeH-Index: 7
view all 22 authors...
6 CitationsSource
#1Triparna Sen (University of Texas MD Anderson Cancer Center)H-Index: 14
#2B. Leticia Rodriguez (University of Texas MD Anderson Cancer Center)H-Index: 2
Last.Lauren Averett Byers (University of Texas MD Anderson Cancer Center)H-Index: 40
view all 19 authors...
29 CitationsSource
#1Jean-Louis PujolH-Index: 31
#2Laurent Greillier (AMU: Aix-Marseille University)H-Index: 18
Last.Pierre-Jean SouquetH-Index: 29
view all 22 authors...
6 CitationsSource
#1Neal Ready (Duke University)H-Index: 32
#2Anna F. Farago (Harvard University)H-Index: 21
Last.Scott J. AntoniaH-Index: 44
view all 15 authors...
23 CitationsSource
#1Leora Horn (Vandy: Vanderbilt University)H-Index: 44
#2Aaron S. MansfieldH-Index: 21
Last.Stephen V. Liu (Georgetown University)H-Index: 18
view all 21 authors...
136 CitationsSource
#1Martin ReckH-Index: 62
#2D. VicenteH-Index: 7
Last.David R. Spigel (Sarah Cannon Research Institute)H-Index: 56
view all 19 authors...
10 CitationsSource
#1Daniel Y. Wang (VUMC: Vanderbilt University Medical Center)H-Index: 8
#2Joe Elie Salem (University of Paris)H-Index: 2
Last.Douglas B. Johnson (VUMC: Vanderbilt University Medical Center)H-Index: 40
view all 27 authors...
88 CitationsSource
#1Igor Bondarenko (Dniepropetrovsk State Medical Academy)H-Index: 18
#2O Juan-VidalH-Index: 1
Last.N ReinmuthH-Index: 1
view all 11 authors...
5 CitationsSource
#1X. ShiH-Index: 1
#2Xiao LiuH-Index: 26
Last.K. CaiH-Index: 1
view all 7 authors...
1 CitationsSource
Cited By0